Completed
PHASE4
INTERVENTIONAL
NCT04636086
Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The objective of the study is to evaluate the clinical efficacy and safety of vitamin D supplementation in hospitalized patients with COVID-19.
Detailed Description
Phase IV, interventional, randomised, double blind, placebo-controlled and parallel study to evaluate the clinical efficacy and safety of vitamin D supplementation in hospitalized patients with COVID-19. Patients will participate in the study for a maximum of 9 weeks, which includes an up to 6-week treatment period and a maximum of 3-week follow-up period. A total of 100 (50 in each group) patients will be randomized in the study and will either receive the test treatment or the placebo treatment.
Interventions
Name:
Cholecalciferol
Type:
DRUG
Description:
Vitamin D supplementation
Name:
Placebo
Type:
OTHER
Description:
Placebo comparator
Primary Outcomes
Measure:
Vitamin D serum concentration
TimeFrame:
Baseline, on days 8, 15, 22, 29 (+/-1 day), or last day of hospitalization, and finally at day 15 to 30 after hospital discharge
Description:
Mean change from screening to end of treatment phase in 25(OH)D3 serum concentration
Trial Information
NCT ID
NCT04636086
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
University of Liege
Last Updated
December 15, 2025